Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice

Gene Therapy

Volumn 8, Issue 5, 2001, Pages 354-361

  Fields, P A ^a   Armstrong, E ^a   Hagstrom, J N ^a   Arruda, V R ^a   Murphy, M L ^b   Farrell, J P ^b   High, K A ^a   Herzog, R W ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adenovirus; C57BL 6 mice; Factor IX; Hemophilia B

Indexed keywords

BLOOD CLOTTING FACTOR 9; FREUND ADJUVANT; INTERLEUKIN 10; VIRUS PROTEIN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG FORMULATION; GENE DELETION; GENE EXPRESSION; GENE THERAPY; HAPLOTYPE; HEMOPHILIA; IMMUNITY; IMMUNOCOMPETENCE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; INBRED STRAIN; INJECTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PERIPHERAL VEIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TRANSGENE;

ADENOVIRIDAE; ADENOVIRUS E1 PROTEINS; ADENOVIRUS E3 PROTEINS; ANIMALS; CELL DIVISION; FACTOR IX; GENETIC VECTORS; HAPLOTYPES; IMMUNE TOLERANCE; INJECTIONS, INTRAVENOUS; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES;

EID: 0035080378     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301409     Document Type: Article

References (42)

1. The incidence of factor VIII inhibitors in patients with severe hemophilia A
2. Factor IX: Molecular structure, epitopes, and mutations associated with inhibitor formation
3. AAV-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy
4. Problems and prospects in gene therapy for hemophilia
5. Evidence for gene transfer and expression of blood coagulation factor IX in patients with severe hemophilia B treated with an AAV vector
6. In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs
7. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose limiting toxicity
8. Adenovirus-mediated expression of therapeutic plasma levels of human factor IX in mice
9. - recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dog
10. Complete short-term correction of canine hemophilia A by in vivo gene therapy
11. Successful expression of human factor IX following repeat administration of an adenoviral vector in mice
12. Human F.IX corrects the bleeding diathesis of mice with hemophilia B
13. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy
14. Upregulation of class I major histocompatibility complex antigens by interferon γ is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo
15. Immune response to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo
16. Inhibitor development and T cell response to human factor VIII in murine hemophilia A
17. Choice of vector determines T cell subsets involved in immune responses against the secreted transgene product factor IX
18. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
19. IL-10 deficient mice are resistant to Leishmania donovani infection
20. Adenovirus-mediated gene transfer: Influence of transgene, mouse strain and type of immune response on persistence of transgene expression
21. Method for multiple portal vein infusions in mice: Quantitation of adenovirus-mediated hepatic gene transfer
22. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains
23. Use of liver-specific promoter reduces immune response to the transgene in adenoviral vectors
24. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers
25. Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes
26. + T cells
27. Interleukin-10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo
28. Interleukin-10 expression is autoregulated at the transcriptional level in human and murine Kupffer cells
29. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: Involvement of NFκB
30. Immune tolerance to a defined heterologous antigen after intrasplenic hepatocyte transplantation - Implications for gene therapy
31. AAV-mediated gene transfer of human blood coagulation factor IX into mouse liver
32. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
33. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
34. The site of rAAV-mediated F.IX expression can significantly influence the level of expression and immunological response to the transgene product
35. Sustained expression of human factor VIII in mice using a parvovirus-based vector
36. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector
37. Therapeutic levels of human factor VIII and IX using HIV-based lentiviral vectors in mouse liver
38. Adenoviral vector-mediated expression of physiological levels of human factor VIII in non-human primates
39. Efficient lentiviral transduction of liver requires cell cycling in vivo
40. Adeno-associated virus vector can be efficiently produced without helper virus
41. Improvements in AAV vector production: Elimination of pseudo-wild-type AAV
42. Enhanced muscle-derived expression of coagulation factor IX from a skeletal actin/CMV hybrid promoter